MEDPAGE Today published an article on March 26, 2021 entitled: “HIPEC Combo Doubles PFS in Advanced Ovarian Cancer” that highlights progression-free survival rates in patients that received HIPEC with a combination of Cisplatin and Paclitaxel versus Cisplatin alone. The data was reported at the March 2021 Society of Gynecological Oncology annual meeting by Laura Chambers, DO, of the Cleveland Clinic. ThermaSolutions is proud to support the Cleveland Clinic in surgical and gynecological cancer treatments with our ThermoChem HT-2000 device. The use of CRS+HIPEC in ovarian cancer has gained more widespread use in recent years, especially after the van Driel et al. study in 2018 (https://www.thermasolutions.com/hipec-in-ovarian-cancer/).
Go to the MEDPAGE article: